Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Capital Leases (2016 - 2024)

Historic Capital Leases for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 8 years, with Q2 2024 value amounting to $3.2 million.

  • Lifecore Biomedical, Inc. \De\'s Capital Leases rose 3.11% to $3.2 million in Q2 2024 from the same period last year, while for May 2024 it was $3.2 million, marking a year-over-year increase of 3.11%. This contributed to the annual value of $3.2 million for FY2024, which is 3.11% up from last year.
  • Latest data reveals that Lifecore Biomedical, Inc. \De\ reported Capital Leases of $3.2 million as of Q2 2024, which was up 3.11% from $3.2 million recorded in Q2 2023.
  • Lifecore Biomedical, Inc. \De\'s Capital Leases' 5-year high stood at $26.4 million during Q2 2020, with a 5-year trough of $12000.0 in Q2 2022.
  • In the last 4 years, Lifecore Biomedical, Inc. \De\'s Capital Leases had a median value of $3.2 million in 2024 and averaged $7.3 million.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Capital Leases crashed by 266.7% in 2020 and then soared by 2668333.33% in 2023.
  • Quarter analysis of 4 years shows Lifecore Biomedical, Inc. \De\'s Capital Leases stood at $26.4 million in 2020, then plummeted by 99.95% to $12000.0 in 2022, then surged by 26683.33% to $3.2 million in 2023, then rose by 0.03% to $3.2 million in 2024.
  • Its Capital Leases stands at $3.2 million for Q2 2024, versus $3.2 million for Q2 2023 and $12000.0 for Q2 2022.